Menu Close
Close

Science Shaping a-
Brighter Future

We’re on a mission to transform biotechnology. With a relentless focus on innovation, our team is dedicated to pushing boundaries and unlocking life’s secrets. Join us as we pioneer breakthroughs that bring us closer to a healthier, more sustainable world. Welcome to the forefront of biotech, where the extraordinary becomes reality.

Our Story

Introducing Our Leadership

Our team is guided by seasoned biopharma executives with outstanding records in advancing and bringing groundbreaking therapies to market.

Click here

Find out more about our Clinical Trials

To find out more about our ongoing or expected clinical trials in order to participate, please get in touch with us through the following link. 

Click here

First-of-its-kind, game changing technologies

ExoNavis has two main technologies under Research and Development

Brain

NAP

A platform to potentially treat Multi Billion-dollar indications within the brain disorder markets such as Autism, Alzheimer’s, Schizophrenia and PSP (Akin to ALS) that results from ADNP deficiencies / imbalances. ADNP is a protein essential for normal brain formation and function.

ExoNavis is about to apply for a New Drug Approval (NDA) for its PSP Indication as well as to enter a Phase 3 human clinical trials on the ADNP Syndrome indication (Autism), both are granted Orphan Drug Designation (ODD) with a great potential in the treatment of various Nerve diseases mentioned above.

Protex

ProtEx

A game changer Exosome based multidrug delivery platform. By leveraging the unique properties of Exosomes (a small cell vesicles), Exonavis’ ProtEx technology enables targeted delivery of proteins while pre-loading them on Exosomes. This unique technology may lead the way to targeted and high efficacy drugs for treatment of various diseases in the filed of genetic disorders, Central Nervous System (CNS) and Cancer. Currently 2 successful POCs on COPD and ARDS indications.

ProtEx platform is expected to dramatically improve clinical results and reduce side effects in patients by enhancing the performance of existing as well as newly developed drugs.

Our science

Current Development Highlights

NAP – ADNP Autism

  • FDA Phase 3 commencing Q4 2024

  • ODD (Orphan Drug Designation) approved by the FDA for ADNP Syndrome (developmental disorder/autism)

  • Received Rare Pediatric Disease (RPD) Designation by the FDA Eligible for Priority Review Voucher from the FDA

  • Protect against MT (Microtubules) disruption leading to tau pathology in Autism and Alzheimer’s disease

  • Restores Neuronal Function: NAP promotes the proper functioning of neurons, addressing core symptoms of ADNP Syndrome.

  • Protects Brain Cells: Offers neuroprotection, safeguarding brain cells from damage associated with ADNP mutations.

  • Enhances Cognitive Abilities: May improves cognitive function, including learning and memory, in individuals with ADNP Syndrome.

  • Reduces Developmental Delays: Supports developmental milestones, potentially reducing delays common in ADNP Syndrome.

  • Modulates Synaptic Connectivity: Helps normalize synaptic connections, improving communication between brain cells.

  • Decreases Neuroinflammation: Lowers inflammation in the brain, which is often elevated in ADNP Syndrome.

NAP – PSP

  • Neuroprotective Properties: NAP helps safeguard neurons from degeneration, a key factor in managing PSP.

  • Stabilizes Microtubules: Supports cellular structure, reducing tau protein buildup, a hallmark of PSP.

  • Reduces Neuroinflammation: Minimizes brain inflammation, potentially slowing PSP progression.

  • Enhances Cognitive Function: Improves memory and cognitive abilities in PSP patients.

  • Promotes Cell Survival: Encourages the survival of brain cells affected by PSP.
  • Potential Disease Modifier: NAP has the potential to alter the course of PSP, addressing the disease at its core.

  • Clinical Relevance: Backed by scientific research, offering a promising new approach for PSP treatment.

ProtEx

  • Efficient Drug Loading: Ensures precise and efficient protein loading during exosome formation, eliminating the need for protein modification.

  • Enhanced Stability: Improves the stability and bioavailability of therapeutic proteins, ensuring effective delivery to target cells.

  • Targeted Delivery: Enables precise targeting of specific tissues or cells, minimizing off-target effects and enhancing treatment efficacy.

  • Reduces Degradation: Protects proteins from degradation during delivery, maintaining their therapeutic potency.

  • Versatile Application: Suitable for a wide range of indications, from neurological disorders to cancer, by customizing the protein payload.

  • Minimizes Immune Response: Lowers the risk of immune reactions compared to traditional delivery methods, enhancing patient safety.
View our project pipeline

Exosome Production Technology

Exonavis is developing a unique production process from cultivation to ready-to-use-dose, using state of the art bioreactors and isolation machinery.

Exonavis has successfully achieved a robust exosome production ability, as well as the characterization protocol of exosomes derived from Mesenchymal stem cells

Discover

Science Shaping a Brighter Future

Copyright 2024 © All rights Reserved to Exonavis